Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8059-0.0041 (-0.51%)
At close: 03:54PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close0.8100
Open0.8000
Bid0.7600 x 1400
Ask0.8080 x 900
Day's Range0.7800 - 0.8150
52 Week Range0.6100 - 2.5000
Volume34,481
Avg. Volume37,132
Market Cap9.441M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.7190
Earnings DateMay 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VRPX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virpax Pharmaceuticals, Inc.
    CAG: Lowering target price to $39.00CONAGRA BRANDS INC has an Investment Rating of HOLD; a target price of $39.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Business Wire

    Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™

    BERWYN, Pa., January 18, 2023--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders, today announced that it will utilize leading pain expert, Dr. Neil K. Singla, to assist in the design and support of the clinical development strategy for Probudur.

  • Business Wire

    Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts

    BERWYN, Pa., January 10, 2023--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that the Company has engaged Destum Partners, Inc. to serve as the exclusive advisor for the Company's partnering and licensing efforts in strategic global markets. This initial engagement will en

  • Business Wire

    Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)

    BERWYN, Pa., January 04, 2023--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has engaged two leading physicians experienced in childhood epilepsy, Dr. Kenneth W. Sommerville and Dr. Lawrence Fried, to support the overall development plan for NobrXiol. Their involve

Advertisement
Advertisement